Drug
Cagrisema
Cagrisema: highest development phase Phase 3, developed by Novo Nordisk. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| CagriSema NCT07919405 | Phase 3 | Hypertension |
| CagriSema (Cagrilintide B and Semaglutide I) NCT07282613 | Phase 3 | Diabetes Mellitus, Type 2 |
Latest
No recent events.
Follow Cagrisema on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.